Companies: 49,246 Total Market Cap: 132441797263938.02

Xlife Sciences AG

SWX-XLS
Healthcare Biotechnology
Rank #21852
Market Cap 142.08 M
Volume 1,612
Price 24.02
Change (%) 4.76%
Country or region Switzerland Switzerland

Xlife Sciences AG's latest marketcap:

142.08 M

As of 05/20/2025, Xlife Sciences AG's market capitalization has reached $142.08 M. According to our data, Xlife Sciences AG is the 21852th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 142.08 M
Revenue (ttm) 1.00 M
Net Income (ttm) 41.17 M
Shares Out 5.74 M
EPS (ttm) 5.45
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 04/25/2025
Market Cap Chart
Data Updated: 05/20/2025

Xlife Sciences AG's yearly market capitalization.

Xlife Sciences AG has seen its market value drop from ₣156.93 M to ₣118.28 M since 2022, representing a total decrease of 24.63% and an annual compound decline rate (CAGR) of 11.16%.
Date Market Cap Change (%)
05/20/2025 ₣118.28 M -19.29%
12/30/2024 ₣145.84 M -47.72%
12/29/2023 ₣278.96 M 77.76%
12/30/2022 ₣156.93 M

Company Profile

About Xlife Sciences AG

Xlife Sciences AG is a dynamic company specializing in the development and commercialization of cutting-edge technologies in the life sciences sector. Founded in 2019 and headquartered in Zurich, Switzerland, the company is dedicated to advancing medical research and therapeutic solutions.

Core Focus Areas

  • Technology Platforms: Identifies novel therapeutic approaches and biomarkers for common diseases using human genetic data.
  • Antibody Development: Engages in the creation of mono- and bispecific anti-tumor antibodies to treat life-threatening diseases.
  • Pharmaceutical Ingredients: Researches, develops, and manufactures chemical and active pharmaceutical ingredients for both human and veterinary medicine.
  • Early Disease Detection: Focuses on the early identification of kidney diseases and neurodegenerative conditions.

Innovative Technologies

Xlife Sciences AG leverages microfluidics-based technologies for functional antibody screening. Additionally, the company offers Neuromex, a specialized screening instrument designed for the early detection of neurodegenerative diseases.

With a commitment to innovation and improving global health, Xlife Sciences AG continues to push the boundaries of life sciences research and development.

Frequently Asked Questions

As of 05/20/2025, Xlife Sciences AG (including the parent company, if applicable) has an estimated market capitalization of $142.08 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Xlife Sciences AG global market capitalization ranking is approximately 21852 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Switzerland
Founded 2019
IPO Date n/a
Employees 17
CEO Oliver Baumann
Sector Healthcare
Industry Biotechnology
Address Talacker 35
Zurich, 8001
Switzerland
Website https://www.xlifesciences.ch
People Also Watch
VRTX
444.31 4.76%
CSL Limited
156.27 4.76%
REGN
605.54 4.76%
KRX-207940
731.22 4.76%